Emerald Acquisition’s Kite Pharma, Inc. KITE Stock Holding History

Emerald Acquisition’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$955K	Buy	17,086 +8,872	+108%	+$494K	﹤0.01%	2153
2016 Q2	$411K	Buy	+8,214	New	+$404K	﹤0.01%	2545

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Emerald Acquisition's KITE Position: Q3 2016 in Review

Emerald Acquisition increased its Kite Pharma, Inc. (KITE) stake by 108% in Q3 2016, buying an estimated $494K and bringing the position to 17,086 shares worth $955K. The position accounts for ﹤0.01% of the portfolio, ranked #2153.

Emerald Acquisition first reported a position in KITE in Q2 2016 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold KITE as of Q3 2016.

Emerald Acquisition held 17,086 shares of Kite Pharma, Inc. worth $955K as of Q3 2016.
Emerald Acquisition bought 8,872 Kite Pharma, Inc. shares in Q3 2016, an estimated $494K.
Kite Pharma, Inc. made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2153 holding.
Emerald Acquisition first reported a position in Kite Pharma, Inc. in Q2 2016 and has held it in 2 quarters since.
195 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.